Trials / Terminated
TerminatedNCT04335578
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
A Multicenter, Randomized, Placebo-Controlled Investigator-Blind, Participant-Blind Study to Evaluate Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft Injury
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to investigate the safety and tolerability of repeat dosing with zampilimab in kidney transplant recipients with deteriorating kidney function associated with chronic allograft injury (CAI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Zampilimab | Participants will receive zampilimab (UCB7858) at pre-specified time-points. |
| DRUG | Placebo | Participants will receive matching placebo (PBO) at pre-specified time-points. |
Timeline
- Start date
- 2019-10-21
- Primary completion
- 2022-05-04
- Completion
- 2022-05-04
- First posted
- 2020-04-06
- Last updated
- 2022-09-21
Locations
5 sites across 4 countries: Australia, Belgium, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04335578. Inclusion in this directory is not an endorsement.